Study of Human Placenta-derived Cells (PDA002) to Evaluate the Safety and Effectiveness in Subjects With PAD and DFU
NCT ID: NCT01859117
Last Updated: 2018-03-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
15 participants
INTERVENTIONAL
2013-05-31
2016-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety, Hemodynamic Effects and Efficacy of Intramuscular PDA-002 in Subjects Who Have Diabetic Foot Ulcer With Peripheral Arterial Disease
NCT02460081
Efficacy and Safety of Intramuscular PDA-002 in Subjects Who Have Diabetic Foot Ulcer With and Without Peripheral Arterial Disease
NCT02264288
A Phase 2 Exploratory Pharmacodynamic Study of HP802-247 in Venous Leg Ulcers
NCT02154087
Placenta Derived Stem Cells for Treating of Chronic Ulcers and Neuropathy
NCT06373809
Adipose Derived Regenerative Cells In the Treatment of Diabetic Foot Ulcers
NCT05095389
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
3 x 10^6 cells
3 x 10\^6 Human Placenta Derived cells (PDA-002) administered intramuscularly on Study Days 1 and 8
3 x 10^6 cells
3 x 10\^6 cells administered on Study Days 1 and 8
10 x 10^6 cells
10 x 10\^6 Human Placenta Derived cells (PDA-002) administered intramuscularly on Study Days 1 and 8
10 x 10^6 cells
10 x 10\^6 cells administered on Study Days 1 and 8
30 x 10^6 cells
30 x 10\^6 Human Placenta Derived cells (PDA-002) administered intramuscularly on Study Days 1 and 8
30 x 10^6 cells
30 x 10\^6 Human Placenta Derived cells (PDA-002) administered intramuscularly on Study Days 1 and 8
100 x 10^6 cells
100 x 10\^6 Human Placenta Derived cells (PDA-002) administered intramuscularly on Study Days 1 and 8
100 x 10^6 cells
100 x 10\^6 cells administered on Study Days 1 and 8
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
3 x 10^6 cells
3 x 10\^6 cells administered on Study Days 1 and 8
10 x 10^6 cells
10 x 10\^6 cells administered on Study Days 1 and 8
30 x 10^6 cells
30 x 10\^6 Human Placenta Derived cells (PDA-002) administered intramuscularly on Study Days 1 and 8
100 x 10^6 cells
100 x 10\^6 cells administered on Study Days 1 and 8
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Males and females, 18 to 80 years of age at the time of signing the informed consent document.
2. Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures are conducted.
3. Able to adhere to the study visit schedule and other protocol requirements.
4. Diabetes mellitus type 2
5. Ischemic or neuro-ischemic diabetic foot ulcer with severity of Grade 1 (full thickness only) or Grade 2 on the Wagner Grading Scale (Appendix A) of greater than one month duration which has not adequately responded to conventional ulcer therapy.
6. Peripheral arterial disease with ankle-brachial index \> 0.6 and ≤ 0.9 or toe-brachial index \> 0.35 and ≤ 0.7.
7. No planned revascularization or amputation over the next 3 months after Screening visit, in the opinion of the Investigator.
8. Not a candidate for peripheral artery percutaneous or surgical revascularization.
9. Screening should not begin until at least 2 weeks after a failed reperfusion intervention and at least 2 months after a successful mechanical intervention.
10. Subject can have stable angina, (Canadian Cardiovascular Society (CCS) Class I-II angina (Appendix H).
11. Subjects should be receiving appropriate medical therapy for hypertension and diabetes.
12. Subject must be a non-tobacco user defined as someone who has not used tobacco/nicotine patch for ≥ 3 months and must agree to remain tobacco/nicotine free for the duration of the study.
13. A female of childbearing potential \[FCBP\] must have a negative serum pregnancy test at Screening and a negative urine pregnancy test prior to treatment with study therapy. In addition, sexually active FCBP must agree to use 2 of the following adequate forms of contraception methods simultaneously such as: oral, injectable, or implantable hormonal contraception; tubal ligation; intrauterine device \[IUD\]; barrier contraceptive with spermicide or vasectomized partner for the duration of the study and the follow-up period.
14. Males (including those who have had a vasectomy) must agree to use barrier contraception (latex condoms) when engaging in reproductive sexual activity with FCBP for the duration of the study and the follow-up period.
Exclusion Criteria
1. Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study.
2. Any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he or she were to participate in the study.
3. Any condition that confounds the ability to interpret data from the study.
4. Subjects whom, in the judgment of the Investigator, are at elevated risk for the development of a malignancy. This judgment may be based on family history, history of industrial exposures, smoking history or other cancer risk factors.
5. Known to be positive for human immunodeficiency virus.
6. Pregnant or lactating females.
7. Subjects with a body mass index \> 35 at Screening.
8. Aspartate transaminase (AST) or Alanine transaminase (ALT) \> 2.5 x the upper limit of normal (ULN) at Screening.
9. Estimated Glomerular Filtration Rate (eGFR) \< 45 mL/min/1.73 m2 at Screening calculated using the Modification of Diet in Renal Disease Study equation (Levey, 2006) or history of eGFR decline \> 15 mL/min/1.73 m2 in the past year.
10. Alkaline phosphatase \> 2.5 x the ULN at Screening.
11. Bilirubin level \> 2 mg/dL (unless subject has known Gilbert's disease) at Screening.
12. Untreated chronic infection or treatment of any infection with systemic antibiotics, including the ulcer site, within 4 weeks prior to dosing with investigational product \[IP\].
13. Known osteomyelitis.
14. History of Methicillin-resistant Staphylococcus aureus (MRSA).
15. Ulcer that has decreased or increased in size by ≥ 50% during the screening period.
16. Uncontrolled hypertension (defined as diastolic blood pressure \> 100 mmHg or systolic blood pressure \> 180 mmHg during Screening at 2 independent measurements taken while subject is sitting and resting for at least 5 minutes).
17. Poorly controlled diabetes mellitus (hemoglobin A1c \> 9%).
18. Untreated proliferative retinopathy.
19. History of malignant ventricular arrhythmia, CCS Class III-IV angina pectoris, myocardial infarction/PCI (percutaneous coronary intervention)/CABG (coronary artery bypass graft) in the preceding 6 months, pending coronary revascularization in the following 2 months, transient ischemic attack/cerebrovascular accident in the preceding 6 months, and/or New York Heart Association \[NYHA\] Stage III or IV congestive heart failure, (Appendix C).
20. Abnormal ECG: new bundle branch block (BBB) ≥ 120 msec in the preceding 3 months; QTcB and/or QTcF \> 480 msec or QTcB and/or QTcF ≥ 500 msec with old BBB. Patients with a potential risk for Torsades des Pointes should not be enrolled.
21. Uncontrolled hypercoagulation.
22. Life expectancy less than 2 years due to concomitant illnesses.
23. In the opinion of the Investigator, the subject is unsuitable for cellular therapy.
24. History of malignancy within 5 years except basal cell or squamous cell carcinoma of the skin or remote history of cancer now considered cured or positive Pap smear with subsequent negative follow-up.
25. History of hypersensitivity to any of the components of the product formulation (including bovine or porcine products, dextran 40, and dimethyl sulfoxide \[DMSO\]).
26. Disorders or allergies precluding the use of radiographic contrast or renal insufficiency severe enough to contraindicate the use of radiographic contrast.
27. Subject has received an investigational agent -an agent or device not approved by the US Food and Drug Administration (FDA) for marketed use in any indication- within 90 days (or 5 half-lives, whichever is longer) prior to treatment with study therapy or planned participation in another therapeutic study prior to the completion of this study.
28. Subject has received previous gene or cell therapy.
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Celularity Incorporated
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Monica E Luchi, MD
Role: STUDY_DIRECTOR
Celularity Incorporated
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Carl T. Hayden Veterans Affairs Medical Center
Phoenix, Arizona, United States
UCLA
Los Angeles, California, United States
Stanford University School of Medicine
Stanford, California, United States
Dr. Wiliam M. Scholl College of Podiatric Medicine
North Chicago, Illinois, United States
Southern Illinois University School of Medicine
Springfield, Illinois, United States
University of North Carolina School of Medicine
Chapel Hill, North Carolina, United States
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, United States
Complete Family Foot Care - McAllen Office
McAllen, Texas, United States
Endeavor Clinical Trials PA
San Antonio, Texas, United States
University of Virginia
Charlottesville, Virginia, United States
University of Wisconsin
Madison, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Francki A, Labazzo K, He S, Baum EZ, Abbot SE, Herzberg U, Hofgartner W, Hariri R; Celgene Cellular Therapeutics Research Group. Angiogenic properties of human placenta-derived adherent cells and efficacy in hindlimb ischemia. J Vasc Surg. 2016 Sep;64(3):746-756.e1. doi: 10.1016/j.jvs.2015.04.387. Epub 2015 Jun 6.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CCT-PDA-002-DFU-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.